Jason Rickard - Aug 8, 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
SVP, Chief Operating Officer
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Aug 8, 2022
Transactions value $
-$344,260
Form type
4
Date filed
8/10/2022, 04:06 PM
Previous filing
May 25, 2022
Next filing
Aug 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale -$317K -27.2K -6.7% $11.64 379K Aug 8, 2022 Direct F1, F2
transaction IRWD Class A Common Stock Sale -$25.8K -2.24K -0.59% $11.56 377K Aug 8, 2022 Direct
transaction IRWD Class A Common Stock Options Exercise $210K +18K +4.79% $11.65 395K Aug 9, 2022 Direct
transaction IRWD Class A Common Stock Sale -$212K -18K -4.57% $11.75 377K Aug 9, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRWD Employee Stock Option (Right to Buy) Options Exercise $0 -18K -100% $0.00* 0 Aug 9, 2022 Class A Common Stock 18K $11.65 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.63 to $11.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The reporting person acquired 2,092 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2022.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.74 to $11.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 This option, granted as an annual performance award, is presently exercisable in full.